What’s up everyone, I have for you today 2 top penny stocks which are strong buy penny stocks
rated by analysts as they have a bright outlook. We have recently covered these two penny stocks on
the channel and they are already making decent positive movements and have a long way to go
based on their latest news. Cathie Woods Ark Invest keeps loading up on one of them,
as well as the Vanguard Group which is a major shareholder across all both plays
as they are very bullish on these two penny stocks, which have catalysts round the corner.
So the key here is that these penny stocks are potential short to medium term plays
and so only get in, if you fully understand their risks, you like their story or business
model and if the price is right for you, as this is not financial advise....
So make sure you don’t miss out on these big bangers, by smashing that like button
as its completely free to do as it helps lots with the YouTube algorithm
and turn on the notification bell to get these hot penny stocks instantly.
Statistics from YouTube show that a large proportion of my viewers are not subscribed to the
channel, so if you do end up enjoying this video, please make sure to subscribe as its also free
and you can always change your mind. I would really appreciate it. Thank you so much.
So let’s get on with it starting with our number 2 penny stock, which is Aquestive Therapeutics,
(AQST). We first covered this penny stock on the channel at $3.6
and it is now sitting at $4.16 with a market cap of $168.7m.
This AQST penny stock has climbed 8.9% on the month but it is still down 20% in 6months. And if
you believe the bulls then this penny stock will be in a different world in by the end of December.
And as mentioned previously, here’s why analysts are keeping an eye on this penny stock
and why it could be on to big big things by Christmas.
They have a track record of success on the back of innovative formulation capabilities,
5 FDA approved products, 2 under FDA review and several in development.
And they recently announced that the FDA has accepted for filing the resubmission of the New
Drug Application (NDA) for Libervant™ Buccal Film for the management of seizure clusters.
The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target goal date of December 23,
2021. If you own this stock you need to save this date in your diaries. Save the
date!! This is the date the FDA is expected to deliver their decision whether or not a approve
a companies New Drug Application. If approved by the FDA for U.S. market access, Libervant
would be the first orally delivered diazepam product for the management of seizure clusters.
AQST has 6 analysts covering the stock, all with strong buy ratings.
The analysts upper price target of $28 per share gives it an upside of over 573%,
and their mid price target of $13.8 per share still gives a modest upside of over 231%
over the next 12months. So which ever way you look at it, analysts are very bullish
on the potential and outcome of the FDA submission due by the end of the year.
In addition to that, analysts are also excited about this penny stock because
they have smashed their earnings estimates and upgraded guidance.
They reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate
of $(0.44) by 25 percent. The company also reported quarterly sales of $15.30 million
which beat the analyst consensus estimate of $9.48 million by 61.39 percent..
And the icing on the cake with this one is that, the company said that other on-going business
activities generated strong operating results during the first half of 2021.
As a result, they have updated their full year expectations for total revenue
to between $46 to $48m up from $38 to $42m and EBITDA loss down to between $39 to $42m
down from a range of $42 to $45m. So not only has this penny stock got a strong
pipeline awaiting FDA approval but they are also revenue generating, smashing analysts forecast
and looking to reduce their losses. So some really really exciting stuff ahead for this penny stock.
The top shareholders on this one are loaded by institutional shareholders with The Vanguard Group
being the second largest shareholder with 1m shares worth 2.69% of all shares outstanding.
And what makes this play equally exciting is that the fourth largest shareholder
Keith Kendall is the CEO with 636k shares worth 1.64%.
He has recently cashed in on 1k worth of shares which is understandable but still holding a vast
majority of his shares. Looking at other insiders, they have mostly acquired positions in AQST
which re-inforces the bullishness in this penny stock. So if you are an AQST army like myself,
please drop a like on this video and let me know in the comments section.
We need to save the date of 23rd December when AQST will be launching the moon and have early
Christmas drinks courtesy of this penny stock. So really really awesome stuff with this one.
Next up to our number 1 penny stock here, which is ConforMIS Inc, the orthopedic medical device
company which features personalized knee and hip replacement products.
It is Nasdaq listed with the ticker number CFMS; We first called it on the channel at $1.46
and it has since climbed to $1.74 and a market cap of $320.7m. It is building on
its strong momentum recently being up 12.6% in the last 5 days and 30.8% over the last month.
I had to load up on this one as I liked its story, business model and the price was right for me
and besides, the addressable market opportunity on this one is just massive
with this Cathie Wood penny stock. So here’s what’s new with Conformis?
In their Second Quarter 2021 Summary, they reported Total revenue of $56.3 million,
an increase of 189% year-on-year, Product revenue of $15.2 million,
an increase of 56% year-on-year, Royalty and licensing revenue of $41.1 million.
They commented that they expect their third quarter product revenue to improve sequentially
from the second quarter and to be in the range of $15.5 million to $16.5 million.
And they believe elective procedure volumes will continue to improve and
approach 2019 levels in the fourth quarter as vaccines become more widely available
and medical facilities recover from pandemic-related staffing impacts.
Conformis, Inc. also Announced the First Procedure Performed Using the Identity Imprint™
Knee Replacement System. The first surgery was successfully performed by Dr. Moby Parsons
at Stratham Ambulatory Surgical Center, in August, 2021,
and he said, “he had long been an advocate of Conformis Image-to-Implant® technology
because he believed it consistently produced excellent outcomes for patients,.
Identity Imprint is a great option for those who elect not to wait for the production
and delivery of a personalized implant. This new system, which is delivered in about three weeks,
helps surgeons optimize implant placement with its iView pre-operative surgical
plan and patient-specific, 3D-printed, single-use iJig surgical instruments.”
So with the number of knee procedures to be performed in ambulatory surgical
centers (ASCs) and outpatient settings expected to grow significantly, Identity Imprint is an
efficient and cost-effective option for those who want to combine traditional lead
times and intraoperative flexibility with the benefits of the Surgery-in-a-Box model.
So by adding Imprint, they believe that they have the best portfolio
to address the changing customer needs and current market dynamics.”
The global knee joint reconstruction market is projected at over $9 billion, with approximately
1 million knee replacements expected to be performed in the United States this year.
So a massive massive addressable market opportunity.
As of August 31st, Ark Invest had been loading up on it becoming the second
largest shareholder with over 13.4m shares worth over 7.2% of all shares outstanding.
The large institutional investor The Vanguard Group and State Street have equally been loading
up on it holding large positions as the 5th and 6th largest shareholders respectively,
which shows their overall bullishness in this penny stock. So exciting times ahead.
So a very interesting and mindblowing prospects ahead for these penny stocks
but only consider getting in if the price is right for you and if you fully understand the
risks. This video is not financial advice, a buy or a sell recommendation, but is meant to
bring some new and exciting penny stocks to your attention for you to do your own research.. As
always I would love to hear from you, so please let me know your thoughts on these penny stocks
in the comments section below and what other high growth penny stocks are catching your eyes lately.
And If you are new to my channel please ensure to subscribe and hit the bell so you are notified
when I upload new videos. If you would like to see more videos like this, please check out this
video right here or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video. Thank you